ReviewFrontiers in immunology2025
Effectiveness and safety of rituximab monotherapy versus conventional regimens for adult idiopathic membranous nephropathy: real-world retrospective study.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The pharmacokinetics and its covariates of rituximab in different clinical populations: a systematic review and narrative synthesis.European journal of clinical pharmacology · 2026Pooled it
- Comparison of efficacy and safety among four therapeutic regimens in primary membranous nephropathy with high anti-PLA2R antibody titers: a single-center retrospective cohort study.BMC nephrology · 2026Article
- Short-term clinical remission rates and adverse reactions of rituximab compared to cyclosporine in patients with refractory membranous nephropathy (MN).American journal of translational research · 2026Article
- Efficacy and safety of different immunosuppressive agents in patients with calcineurin inhibitor-dependent primary membranous nephropathy.Frontiers in medicine · 2026Article
- Optimized RTX strategy plus structured glucocorticoid tapering for primary membranous nephropathy: a multicenter propensity score-matched cohort study.Frontiers in molecular biosciences · 2026Article
- Clinical evaluation of rituximab combined with ACE inhibitors and statins in refractory nephrotic syndrome: associations with proteinuria, lipid profiles, and podocyte-related biomarkers.Frontiers in pharmacology · 2026Article
- Contemporary review of primary membranous nephropathy.Frontiers in immunology · 2026Review
Corrections and comments
- Erratum issued
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The 2021 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend immunotherapeutic regimens for idiopathic membranous nephropathy (IMN), including glucocorticoids (GC) with cyclophosphamide (CYC) or calcineurin inhibitors (CNIs), as well as biologics. However, the comparative effectiveness remains insufficiently explored. This study aimed to evaluate the effectiveness and safety of rituximab (RTX) versus conventional regimens. Methods: This study retrospectively included 310 IMN patients diagnosed with nephrotic syndrome (NS), who were divided into three groups: RTX group (n=62), glucocorticoid with cyclophosphamide (GC+CYC) group (n=124), and glucocorticoid with calcineurin inhibitor (GC+CNI) group (n=124). Treatment effectiveness and safety were assessed at the 12 months. The primary endpoint was clinical remission at 12 months. Secondary endpoints, included clinical remission rate, relapse rate, and safety and occurrence of adverse events(AEs)at 24 months. Results: At 12 months, 44/62 (71.0%) achieved clinical remission, with 18 (29.0%) achieving CR in the rituximab group,. In the GC+CYC group, 90/124 (72.6%) achieved clinical remission, 48 (38.7%) achieving CR. In the GC+CNI group, 97/124 (78.2%) achieved clinical remission, with 52 (41.9%) achieving CR. At 24 months, 33/35 (94.3%) achieved clinical remission, with 18 (51.4%) achieving CR in the RTX group. In the GC+CYC group, 102/115 (88.7%) achieved clinical remission, with 44 (38.3%) achieving CR. In the GC+CNI group, 98/114(86.0%) achieved clinical remission, with 47 (41.2%) achieving CR. The clinical and complete remission rates were significantly higher in the rituximab group than in the conventional treatment groups (clinical remission: 94.3% vs. 88.7% vs. 86.0%, Conclusion: Rituximab demonstrated non-inferior clinical remission rates at 12 months compared to CYC and CNIs. Rituximab was also associated with lower relapse rates and better safety profile. These findings suggest that rituximab offers distinct advantages in maintaining long-term clinical remission and may be considered an effective treatment regimen for IMN patients at risk of disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.